A novel PKB/Akt inhibitor, MK-2206,effectively inhibits insulin-stimulated glucose metabolism and protein synthesis in isolated rat skeletal muscle

Chemistry

• MK-2206 100%
• Protein Kinase B Inhibitor 80%
• Protein Synthesis 46%
• Pharmacological Metabolism 34%
• Glucose 32%
• Glycogen 24%
• Protein 18%
• Insulin Derivative 16%
• Disorder 3%
• Metabolic 3%
• Dose 3%
• Resistance 2%
• Probe 2%

Medicine & Life Sciences

• MK 2206 72%
• Proto-Oncogene Proteins c-akt 53%
• Skeletal Muscle 35%
• Insulin 30%
• Glucose 28%
• Proteins 16%
• Glycogen 10%
• Phosphorylation 9%
• Protein Kinase Inhibitors 7%
• Peptide Elongation Factor 2 5%
• Eukaryotic Initiation Factor-4E 5%
• Ribosomal Protein S6 Kinases 4%
• Glycogen Synthase Kinase 3 4%
• Glycogen Synthase 4%
• TOR Serine-Threonine Kinases 3%
• Proline 3%
• Carrier Proteins 2%
• Insulin Resistance 2%
• Neoplasms 2%
• Growth 1%